Beam Therapeutics
CAMBRIDGE, MA · Founded 2017 · CIK 0001745999 · Biotech
Base editing therapies for genetic medicine
beamtx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $180M
- 2 Form D · Mar 2019
- 91 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 7 granted · 33 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20182019
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $44,999,981 | |
| Private capital raised | Form D · SEC | $135,000,002 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1270 | NEUROEPIGENIX, LLC | — | — |
| 1271 | Third Harmonic Bio | — | — |
| 1272 | BridgeBio Oncology Therapeutics | — | — |
| 1273 | Beam Therapeutics | — | $180M |
| 1274 | SYNSPIRA THERAPEUTICS, INC. | — | — |
| 1275 | NANOTHERAPEUTICS, INC. | — | — |
| 1276 | FIBROPLATE INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- KRISTINA BUROWDirector
- JOHN EVANSDirector · Executive Officer
- MARK FISHMANDirector
- CAROLE HODirector
- STEPHEN KNIGHTDirector
- ROBERT NELSENDirector
- ROBERT NELSONDirector
- MICHAEL YIDirector
- FENG ZHANGDirector
Patents
- Prime Editing Of Single Base Mutations In Sickle Cell Diseaseapplication
- Compositions And Methods For Altering Complement Activationapplication
- Compositions And Methods For Treating ALPHA-1 Antitrypsin Deficiencyapplication
- Methods And Compositions For Treating ALPHA-1 Antitrypsin Deficiencyapplication
- Nanomaterials Comprising Triolsapplication
- Nucleobase Editors Having Reduced Non-target Deamination And Assays For Characterizing Nucleobase Editorsapplication
- Compositions And Methods For Base Editing A Phenylalanine Hydroxylase Polynucleotideapplication
- Immunosuppressant-resistant Modified Allogeneic Modified Immune Cells And Methods For Use Thereofapplication
- Compositions And Methods For Altering A Nucleobase In A Lipoprotein(a) Polynucleotideapplication
- Ionizable Lipids With Linear Head Groupsapplication
- Compositions And Methods For Delivering A Nucleobase Editing Systemapplication
- Ionizable Lipids With Branched Head Groupsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.